Northwest Biotherapeutics reported $11.39M in Operating Expenses for its fiscal quarter ending in March of 2026.





Operating Expenses Change Date
Agenus USD -199.08M 22.15M Jun/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Celldex Therapeutics USD 714.56M 258.34M Jun/2026
Eisai JPY 209.6B 6.14B Jun/2026
Merck USD 15.77B 2.4B Jun/2026
Northwest Biotherapeutics USD 11.39M 120.04M Mar/2026
Pfizer USD 85.19B 4.91B Jun/2026
Plus Therapeutics USD 8.15M 1.04M Mar/2026
Roche Holding CHF 18.9B 2.12B Jun/2026